Q1 2024 Financial Results and Corporate Update

May 8, 2024



Disclaimer

This presentation contains forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995. The forward-looking statements involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management and expected market growth are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements include, but are not limited to, statements about early clinical data, regulatory approvals, clinical trial timing and plans, the achievement of clinical and commercial milestones, future financial and operating results, including 2024 financial guidance and anticipated future cash and cash equivalents, business strategies, market opportunities, financing, and other statements that are not historical facts. Our product candidates and related technologies are novel approaches to cancer treatment that present significant challenges. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including but not limited to: risks associated with our financial condition and need for additional capital; risks associated with the Company's development work, including any delays or changes to the timing, cost and success of our product development activities and clinical trials including if we encounter difficulties enrolling patients in our clinical trials; the risks of delays in FDA and/or EU approval of our drug candidates or failure to receive approval; the risks related to commercializing any approved new pharmaceutical product including the rate and degree of market acceptance of our product candidates; development of our sales and marketing capabilities and risks associated with failure to obtain sufficient reimbursement for our products; risks related to our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into collaboration or alliances with partners; risks associated with protection of our intellectual property rights; and other risks and uncertainties affecting the Company including those described in the "Risk Factors" section included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and other reports the Company files from time to time with the Securities and Exchange Commission. Any forward-looking statements contained in this presentation speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Mike Rossi

President and CEO

Company Overview

Agenda

1. **Company Overview**
   Mike Rossi, President and Chief Executive Officer
2. **DANYELZA Global Sales**
   Sue Smith, Chief Commercial Officer
3. **Naxitamab Development Program**
   Vignesh Rajah, MBBS, DCH, MRCP, Chief Medical Officer
4. **Q1 2024 Financials**
   Bo Kruse, Chief Financial Officer
5. **Q&A**
   All and **Thomas Gad**, Founder and Chief Business Officer

DANYELZA Highlights

- Q1 2024 **U.S. DANYELZA net product revenues of $18.6 million, ↑ 11% YoY**

- **63 sites activated** to date since DANYELZA commercial launch
- **5 new accounts** added in Q1 2024

- **Continued global expansion** with China commercial progress
- Partner Adium **launched in Brazil and Mexico** in Q2 2024

- **Ongoing ISS trials** progressing with MSK osteosarcoma data readout anticipated in Q4 2024; WEP NPP* in Europe ongoing

*Named Patient Program

Study 1001: GD2-SADA Phase I Clinical Trial – Dosing Patients in Part A

Theranostic approach using a 30 mCi ^{177}Lu-DOTA imaging dose before exposing to therapeutic dose

Trial Update:

- Solid tumors (SCLC, malignant melanoma, sarcomas)
- Completed Cohorts 1, 2 and 3; currently in Cohort 4*
- 14 patients dosed*
- 7 sites open*; planning to add additional sites

Part A
N = 15 - 18

Protocol allows for GD2–SADA protein dose-escalation from 0.3 mg/kg to 10 mg/kg with a therapeutic ^{177}Lu-DOTA dose of 100-200 mCi (7.4 GBq) – the interval between SADA and payload to be explored

Part B
N = 9 - 12

^{177}Lu-DOTA therapeutic dose escalation from 400 mCi (14.8 GBq) to 750 mCi (27.8 GBq). Patients to receive up to 2 cycles

Part C
5 cycles

Repeated dosing up to 5 cycles

* As of May 8, 2024

Study 1201: Planned CD38-SADA Phase I Clinical Trial Design

Theranostic approach using CD38 positivity on IHC and ^{177}Lu-DOTA organ dosimetry before repeat dosing in patients with relapsed or refractory non-Hodgkin Lymphoma

Trial Update:

- IND approved by U.S. FDA in Q4 2023
- Anticipate activating first sites in Q2 2024

Part A
N = 12 - 15

CD38-SADA dose-escalation with fixed imaging and therapeutic ^{177}Lu-DOTA doses

Part B
N = 12 - 15

^{177}Lu-DOTA therapeutic dose escalation with the CD38-SADA dose determined in Part A

Mike Rossi

President and CEO

Company Overview

Sue Smith

Chief Commercial Officer

Global DANYELZA Sales

Q1 2024 DANYELZA Global Commercial Update

- Q1 2024 **U.S. DANYELZA net product revenues of $18.6 million, ↑ 11% YoY**
- Majority of total sales in U.S.; additional sales recorded in China, LATAM

- **63 U.S. accounts** to date since initial launch; **5 new accounts** added in Q1 2024
- **18 U.S. HCPs prescribed** DANYELZA in Q1 2024; **106 U.S. HCPs prescribed** DANYELZA since launch with 31 HCPs starting 2+ patients*

- Added to **3 hospital formularies** in Q1 2024; added to **44 hospital formularies** to date since the initial launch*
- DANYELZA remains a **leading therapy** in U.S. anti-GD2 market

- CMED agreement on DANYELZA price in Brazil
- **Brazil and Mexico launched** in April 2024

*As of March 31, 2024

Vignesh Rajah

Chief Medical Officer

Naxitamab Development Program



Ongoing Naxitamab Clinical Trials

Beat Childhood Cancer RESEARCH CONSORTIUM

- Phase II BCC multi-center trial evaluating naxitamab + standard induction therapy in patients with newly diagnosed HR NB
- 16 sites initiated to date; target 40-50 sites in U.S. and Canada
- 7 patients dosed to date; target 76 total patients

Anticipate transitioning to a multi-center randomized trial in Q2 2024

Memorial Sloan Kettering Cancer Center

- Multi-center Phase II trial investigating naxitamab in patients with relapsed osteosarcoma
- Anticipated data readout from MSKCC in Q4 2024

Prepared to initiate pivotal randomized trial in Q2 2025 following data readout from MSK

The Ohio State University COMPREHENSIVE CANCER CENTER

- ISS Phase Ib/II trial investigating TGFβ NKs, gemcitabine + naxitamab in patients with metastatic breast cancer
- Target enrollment of 42 patients
- Anticipate first patient to be dosed in Q2 2024

Potential multi-center Phase II study based on the results from Phase Ib

Institute of Mother and Child

- Randomized Phase II trial evaluating efficacy and safety of naxitamab in patients with refractory Ewing sarcoma initiated in Q4 2023
- 3 patients dosed in naxitamab arm to date; target 24 patients total (16 naxitamab, 8 control)

Anticipated study completion in 2028

Clinicaltrials.gov: BCC trial NCT05489887, MSK trial NCT02502786, OSU trial NCT06026657

Bo Kruse

Chief Financial Officer

Q1 2024 Financials

Key Q1 2024 Financial Highlights

Revenue

	Three months ended Mar 31,	
	2024	**2023**
Net product revenue	$19.4 M	$20.3M
License revenue	$0.5 M	–
Total revenue	**$19.9 M**	**$20.3 M**

Net product revenue
↓ 4% YoY

Key Q1 2024 Financial Highlights

Operating Expenses

	Three months ended Mar 31,	
	2024	**2023**
Cost of goods sold	$2.1 M	$2.1 M
License royalties	$0.05 M	–
Research & development	$13.3 M	$13.4 M
Selling, general & admin	$11.4 M	$12.3 M
Total OpEx	**$26.8 M**	**$27.8 M**

↓ 3% YoY

Key Q1 2024 Financial Highlights

Net Loss

	Three months ended Mar 31,	
	2024	2023
Net loss	$(6.6) M	$(6.4) M
Net loss per basic, diluted share	$(0.15)	$(0.15)

Net loss
relatively flat YoY

Key Q1 2024 Financial Highlights

Responsible stewards of capital

	As of	
	Mar 31, 2024	Dec 31, 2023
Cash and cash equivalents	$75.7 M	$78.6 M

Anticipated cash runway
into 2027*

	Three months ended Mar 31,	
	2024	2023
Cash use	$2.9 M	$13.1 M

Quarterly cash use
↓ 78% YoY

*This estimate reflects the Company's current business plan and is supported by assumptions that may prove to be inaccurate, such that Y-mAbs could use its available capital resources sooner than it currently expects.

Reiterate Financial Guidance for Full Year 2024

DANYELZA Net Product Revenues:	**$95 million to $100 million**
Total Operating Expenses:	**$115 million to $120 million**
Total Expected Cash Burn:	**$15 million to $20 million**

Cash and cash equivalents anticipated to support operations as currently planned into 2027*

** This estimate reflects the Company's current business plan and is supported by assumptions that may prove to be inaccurate, such that Y-mAbs could use its available capital resources sooner than it currently expects.*

Q&A

Mike Rossi
President and
Chief Executive Officer

Sue Smith
Chief Commercial Officer

Vignesh Rajah, MBBS, DCH, MRCP
Chief Medical Officer

Thomas Gad
Founder, Vice Chair,
Chief Business Officer

Bo Kruse
Chief Financial Officer


Thank You